Ablysinol

(dehydrated alcohol)

ApprovedSmall molecule

CSL Behring

Ablysinol is one of 125 small molecule programs targeting Clinical Trial. It is currently in Approved.

Indications

Total Trials

Active Trials

124

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Clinical TrialActive, not recruiting

CancerActive, not recruiting

Pancreatic CancerCompleted

Clinical TrialPhase 3

Active, not recruiting

CancerPhase 1

Active, not recruiting

Pancreatic CancerApproved

Completed

Competition

Competitive Landscape

335 competitors in Pancreatic Cancer

#DrugCompanyPhaseTrials

Ablysinol

CSL Behring

Approved

1 2

Medrol

Pfizer

Preclinical

1 3

Byetta

AstraZeneca

Preclinical

1 4

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

1 5

Ayvakit Sprinkle

MMemorial Sloan Kettering Cancer Center

Preclinical

1 6

Xylocaine

MMEDRx USA, Inc.

Preclinical

1 7

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 8

Sulfonylureas

Eli Lilly

Preclinical

1 9

Active Comparator

Moderna

Preclinical

1 10

Cyclophosphamid

EEssen Biotech

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Treatment1 trial

Safety/Tolerability Study of Alcohol Injection for Treatment of BPH (Enlarged Prostate)

Completed·AAmerican Medical Systems·Phase 1/2·NCT00037141·150 enrolled

Pancreatic Cancer1 trial

Endoscopic Ultrasound-guided Celiac Plexus Neurolysis (EUS-CPN)With Alcohol in Unresectable Pancreatic Cancer: a Pilot Study

Completed·IIndiana University·Phase 4·NCT00578279·20 enrolled

Clinical Trial1 trial

TARGET BP I Clinical Trial

Active, not recruiting·AAblative Solutions, Inc.·Phase 3·NCT02910414·300 enrolled

Cancer1 trial

Long Acting Neuraxial Peri-prostatic Block in Cancer

Active, not recruiting·IIcahn School of Medicine at Mount Sinai·Phase 1·NCT06703437·12 enrolled

Regulatory

FDA Approval Timeline[4]

Jun 21, 2018

ABLYSINOL

NDA NDA207987

Oct 23, 2025

DEHYDRATED ALCOHOL

NDA NDA214988

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for dehydrated alcohol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — dehydrated alcohol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for dehydrated alcohol. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA214988). U.S. Food & Drug Administration.
[5]
SEC EDGAR — CSL Behring company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: CSL Behring

Ablysinol

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Treatment1 trial

Pancreatic Cancer1 trial

Clinical Trial1 trial

Cancer1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News